FAF2
Gene Information
- Official Symbol: FAF2
- Official Name: Fas associated factor family member 2
- Aliases and Previous Symbols: N/A
- Entrez ID: 23197
- UniProt: Q96CS3
- Interactions: BioGRID
- PubMed articles: Open PubMed
- OMIM: Open OMIM
Function Summary
- Entrez Summary: N/A
- UniProt Summary: Plays an important role in endoplasmic reticulum- associated degradation (ERAD) that mediates ubiquitin-dependent degradation of misfolded endoplasmic reticulum proteins (PubMed:18711132, PubMed:24215460). Involved in inhibition of lipid droplet degradation by binding to phospholipase PNPL2 and inhibiting its activity by promoting dissociation of PNPL2 from its endogenous activator, ABHD5 which inhibits the rate of triacylglycerol hydrolysis (PubMed:23297223). {ECO:0000269|PubMed:18711132, ECO:0000269|PubMed:23297223, ECO:0000269|PubMed:24215460}.
Pfam Domains GO Terms
Pfam Domains
| UBX |
GO Terms
| lipase inhibitor activity |
| lipase binding |
| VCP-NPL4-UFD1 AAA ATPase complex |
| retrograde protein transport, ER to cytosol |
| endoplasmic reticulum to cytosol transport |
| lipid droplet organization |
| protein exit from endoplasmic reticulum |
| ubiquitin-dependent ERAD pathway |
| ubiquitin binding |
| lipid droplet |
| ERAD pathway |
| azurophil granule lumen |
| response to unfolded protein |
| response to topologically incorrect protein |
| response to endoplasmic reticulum stress |
| ubiquitin protein ligase binding |
| proteasome-mediated ubiquitin-dependent protein catabolic process |
| proteasomal protein catabolic process |
| neutrophil degranulation |
| neutrophil activation involved in immune response |
| neutrophil mediated immunity |
| neutrophil activation |
| granulocyte activation |
| leukocyte degranulation |
| myeloid leukocyte mediated immunity |
| myeloid cell activation involved in immune response |
| ubiquitin-dependent protein catabolic process |
| modification-dependent protein catabolic process |
| modification-dependent macromolecule catabolic process |
| myeloid leukocyte activation |
| proteolysis involved in cellular protein catabolic process |
| cellular protein catabolic process |
| leukocyte activation involved in immune response |
| cell activation involved in immune response |
| protein catabolic process |
| regulated exocytosis |
| leukocyte mediated immunity |
| negative regulation of catalytic activity |
| exocytosis |
| cellular macromolecule catabolic process |
| leukocyte activation |
| intracellular protein transport |
| response to organonitrogen compound |
| secretion by cell |
| endoplasmic reticulum |
| export from cell |
| macromolecule catabolic process |
| organonitrogen compound catabolic process |
| cell activation |
| response to nitrogen compound |
| immune effector process |
| secretion |
| negative regulation of molecular function |
| proteolysis |
| protein transport |
| intracellular transport |
| peptide transport |
| amide transport |
| cellular protein localization |
| cellular macromolecule localization |
| establishment of protein localization |
| cellular response to stress |
| organic substance catabolic process |
| cellular catabolic process |
| establishment of localization in cell |
| nitrogen compound transport |
| immune response |
| extracellular region |
| vesicle-mediated transport |
CRISPR Data
Compound Hit Most Correlated Genes in Chemogenomics Tissues where Essential in the Avana Dataset (DepMap 20Q1)
Compound Hit
Most Correlated Genes in Chemogenomics
| Gene | Correlation |
|---|---|
| PLAA | 0.693 |
| BAK1 | 0.691 |
| UBQLN1 | 0.676 |
| UBE2G2 | 0.671 |
| APAF1 | 0.653 |
| VDAC2 | 0.65 |
| DOHH | 0.633 |
| CYCS | 0.595 |
| RPTOR | 0.592 |
| MARCH5 | 0.592 |
| CASP9 | 0.591 |
| SERF2 | 0.589 |
| HARS | 0.565 |
| HSPD1 | 0.558 |
| KDSR | 0.558 |
| DIABLO | 0.549 |
| THG1L | 0.546 |
| MTOR | 0.535 |
| ENY2 | 0.526 |
| GABPA | 0.516 |
| GFPT1 | 0.513 |
| RNMT | 0.511 |
| ATP5J | 0.507 |
| TRIM28 | 0.506 |
| ROMO1 | 0.504 |
| HCCS | 0.503 |
| BAP1 | 0.501 |
| ATAD1 | 0.501 |
| BPTF | 0.5 |
| WDR24 | 0.498 |
| NSD1 | 0.498 |
| UAP1 | 0.494 |
| VHL | 0.492 |
| ZZZ3 | 0.49 |
| AUP1 | 0.484 |
| GMPPB | 0.48 |
| METAP2 | 0.475 |
| EIF4E | 0.474 |
| TRIAP1 | 0.474 |
| ATP5I | 0.471 |
| PPP2R3C | 0.468 |
| MFN1 | 0.464 |
| TADA2A | 0.463 |
| SRP14 | 0.46 |
| DHPS | 0.458 |
| SUV420H1 | 0.456 |
| NAE1 | 0.454 |
| ID3 | 0.454 |
| ALG1 | 0.448 |
| MEAF6 | 0.442 |
| MLST8 | 0.441 |
| ATP5A1 | 0.44 |
| ATP5O | 0.437 |
| UBE2K | 0.436 |
| STAU1 | 0.436 |
| RAD23B | 0.435 |
| PPA2 | 0.435 |
| WDR59 | 0.435 |
| RTCB | 0.434 |
| DPAGT1 | 0.433 |
| PMM2 | 0.432 |
| CTDNEP1 | 0.431 |
| UBE2J1 | 0.431 |
| CEPT1 | 0.431 |
| LAMTOR5 | 0.431 |
| OPA1 | 0.43 |
| UTP23 | 0.428 |
| PELO | 0.428 |
| EXOC4 | 0.428 |
| SRRD | 0.425 |
| DDX42 | 0.423 |
| SEH1L | 0.421 |
| PDPK1 | 0.417 |
| DDHD2 | 0.416 |
| PPP6C | 0.415 |
| TAF4 | 0.412 |
| ATP5B | 0.412 |
| UBE2M | 0.411 |
| DHRSX | 0.409 |
| DAD1 | 0.409 |
| KCTD5 | 0.407 |
| BRWD1 | 0.406 |
| PIK3R4 | 0.405 |
| DNAJC3 | 0.404 |
| EXOC3 | 0.404 |
| ELP3 | 0.403 |
| CUL3 | 0.403 |
| TAZ | 0.4 |
| ALG5 | 0.4 |
| TIMM13 | 0.4 |
| CBFB | 0.4 |
Tissues where Essential in the Avana Dataset (DepMap 20Q1)
Global Fraction of Cell Lines Where Essential: 128/739
| Tissue | Fraction Of Cell Lines Where Essential |
|---|---|
| 1290807.0 | 0/1 |
| 909776.0 | 0/1 |
| bile duct | 5/28 |
| blood | 4/28 |
| bone | 2/26 |
| breast | 2/33 |
| central nervous system | 11/56 |
| cervix | 0/4 |
| colorectal | 2/17 |
| esophagus | 5/13 |
| fibroblast | 0/1 |
| gastric | 0/16 |
| kidney | 10/21 |
| liver | 6/20 |
| lung | 12/75 |
| lymphocyte | 4/16 |
| ovary | 6/26 |
| pancreas | 5/24 |
| peripheral nervous system | 0/16 |
| plasma cell | 11/15 |
| prostate | 0/1 |
| skin | 1/24 |
| soft tissue | 1/9 |
| thyroid | 1/2 |
| upper aerodigestive | 0/22 |
| urinary tract | 5/29 |
| uterus | 1/5 |
Essentiality in NALM6
- Essentiality Rank: 2654
- Expression level (log2 read counts): 7.07
Expression Distribution
FAF2 Expression in NALM6 Cells: 7.07
